Secreted osteoclastogenic factor of activated T cells (SOFAT), a novel osteoclast activator, in chronic periodontitis

Human Immunology

Volumn 74, Issue 7, 2013, Pages 861-866

  Jarry, Christian Rado ^a   Duarte, Poliana Mendes ^b   Freitas, Fabiana Furtado ^c   Macedo, Cristina Gomes de ^c   Clemente Napimoga, Juliana Trindade ^c   Saba Chujfi, Eduardo ^a   Passador Santos, Fabricio ^a   Araújo, Vera Cavalcanti de ^a   Napimoga, Marcelo Henrique ^a  

^a SÃO LEOPOLDO MANDIC INSTITUTE AND RESEARCH CENTER   (Brazil)

^b GUARULHOS UNIVERSITY   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CYTOKINE; EOSIN; HEMATOXYLIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; SECRETED OSTEOCLASTOGENIC FACTOR OF ACTIVATED T CELL; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CHRONIC PERIODONTITIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GINGIVAL BIOPSY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAXILLA; MOLAR TOOTH; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PERIODONTAL LIGAMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ACID PHOSPHATASE; ADULT; ANIMALS; CELL LINE; CELLS, CULTURED; CHRONIC PERIODONTITIS; CYTOKINES; FEMALE; HUMANS; ISOENZYMES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND; T-LYMPHOCYTES;

EID: 84878576086     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.04.013     Document Type: Article

References (35)

1. Krauss J.L., Potempa J., Lambris J.D., Hajishengallis G. Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host. Periodontol 2000 2010, 52:141-162.
2. Tonetti M.S., Claffey N. European Workshop in Periodontology group C. Advances in the progression of periodontitis and proposal of definitions of a periodontitis case and disease progression for use in risk factor research. Group C consensus report of the 5th European Workshop in Periodontology. J Clin Periodontol 2005, 32:210-213.
3. Graves D.T., Fine D., Teng Y.T., Van Dyke T.E., Hajishengallis G. The use of rodent models to investigate host-bacteria interactions related to periodontal diseases. J Clin Periodontol 2008, 35:89-105.
4. Liu Y.C., Lerner U.H., Teng Y.T. Cytokine responses against periodontal infection: protective and destructive roles. Periodontol 2000 2010, 52:163-206.
5. Garlet G.P. Destructive and protective roles of cytokines in periodontitis: a re-appraisal from host defense and tissue destruction viewpoints. J Dent Res 2010, 89:1349-1363.
6. Graves D.T. The potential role of chemokines and inflammatory cytokines in periodontal disease progression. Clin Infect Dis 1999, 28:482-490.
7. Teng Y.T., Nguyen H., Gao X., Kong Y.Y., Gorczynski R.M., Singh B., et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000, 106:1259-1267.
8. Graves D.T., Li J., Cochran D.L. Inflammation and uncoupling as mechanisms of periodontal bone loss. J Dent Res 2011, 90:143-153.
9. Garlet G.P., Cardoso C.R., Campanelli A.P., Ferreira B.R., Avila-Campos M.J., Cunha F.Q., et al. The dual role of p55 tumour necrosis factor-alpha receptor in Actinobacillus actinomycetemcomitans-induced experimental periodontitis: host protection and tissue destruction. Clin Exp Immunol 2007, 147:128-138.
10. Garlet G.P., Cardoso C.R., Campanelli A.P., Garlet T.P., Avila-Campos M.J., Cunha F.Q., et al. The essential role of IFN-gamma in the control of lethal Aggregatibacter actinomycetemcomitans infection in mice. Microbes Infect 2008, 10:489-496.
11. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
12. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
13. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
14. Hofbauer L.C., Kühne C.A., Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004, 4:268-275.
15. Lewiecki E.M. Treatment of osteoporosis with denosumab. Maturitas 2010, 66:182-186.
16. Crotti T., Smith M.D., Hirsch R., Soukoulis S., Weedon H., Capone M., et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003, 38:380-387.
17. Kawai T., Matsuyama T., Hosokawa Y., Makihira S., Seki M., Karimbux N.Y., et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006, 169:987-998.
18. Teng Y.T. Protective and destructive immunity in the periodontium: Part 1-innate and humoral immunity and the periodontium. J Dent Res 2006, 85:198-208.
19. Weitzmann M.N., Cenci S., Rifas L., Haug J., Dipersio J., Pacifici R. T cell activation induces human osteoclast formation via receptor activator of nuclear factor κB ligand-dependent and -independent mechanisms. J Bone Miner Res 2001, 16:328-337.
20. Rifas L., Weitzmann M.N. A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum 2009, 60:3324-3335.
21. Hassumi M.Y., Silva-Filho V.J., Campos-Júnior J.C., Vieira S.M., Cunha F.Q., Alves P.M., et al. PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis. Int Immunopharmacol 2009, 9:1150-1158.
22. Kostenuik P.J., Nguyen H.Q., McCabe J., Warmington K.S., Kurahara C., Sun N., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009, 24:182-195.
23. Napimoga M.H., Benatti B.B., Lima F.O., Alves P.M., Campos A.C., Pena-Dos-Santos D.R., et al. Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int Immunopharmacol 2009, 9:216-222.
24. Rodrigues W.F., Madeira M.F., da Silva T.A., Clemente-Napimoga J.T., Miguel C.B., Dias-da-Silva V.J., et al. Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation. Br J Pharmacol 2012, 165:2140-2151.
25. Napimoga M.H., da Silva C.A., Carregaro V., Farnesi-de-Assunção T.S., Duarte P.M., de Melo N.F., et al. Exogenous administration of 15d-PGJ2-loaded nanocapsules inhibits bone resorption in a mouse periodontitis model. J Immunol 2012, 189:1043-1052.
26. Jin Q., Cirelli J.A., Park C.H., Sugai J.V., Taba M., Kostenuik P.J., et al. RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol 2007, 78:1300-1308.
27. Armitage G.C. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999, 4:1-6.
28. Duarte P.M., Napimoga M.H., Fagnani E.C., Santos V.R., Bastos M.F., Ribeiro F.V., et al. The expression of antioxidant enzymes in the gingivae of type 2 diabetics with chronic periodontitis. Arch Oral Biol 2012, 57:161-168.
29. Araujo M.W., Hovey K.M., Benedek J.R., Grossi S.G., Dorn J., Wactawski-Wende J., et al. Reproducibility of probing depth measurement using a constant-force electronic probe: analysis of inter- and intra- examiner variability. J Periodontol 2003, 74:1736-1740.
30. Napimoga M.H., Nunes L.H.A.C., Maciel A.A.B., Demasi A.P.D., Benatti B.B., Santos V.R., et al. Possible involvement of IL-21 and IL-10 on salivary IgA levels in chronic periodontitis subjects. Scand J Immunol 2011, 74:596-602.
31. Duarte P.M., Miranda T.S., Lima J.A., Dias-Gonçalves T.E., Santos V.R., Bastos M.F., et al. Expression of immune-inflammatory markers in sites of chronic periodontitis in patients with type 2 diabetes. J Periodontol 2012, 83:426-434.
32. Tanaka S., Nakamura K., Takahasi N., Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005, 208:30-49.
33. Koide M., Kinugawa S., Takahashi N., Udagawa N. Osteoclastic bone resorption induced by innate immune responses. Periodontol 2000 2010, 54:235-246.
34. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191:275-286.
35. Rifas L., Avioli L.V. A novel T cell cytokine stimulates interleukin-6 in human osteoblastic cells. J Bone Miner Res 1999, 14:1096-1103.